Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.

Mod Pathol

1] Department of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, BC, Canada [2] Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada.

Published: January 2014


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Ovarian endometrioid carcinomas and endometrial endometrioid carcinomas share many histological and molecular alterations. These similarities are likely due to a common endometrial epithelial precursor cell of origin, with most ovarian endometrioid carcinomas arising from endometriosis. To directly compare the mutation profiles of two morphologically similar tumor types, endometrial endometrioid carcinomas (n=307) and ovarian endometrioid carcinomas (n=33), we performed select exon capture sequencing on a panel of genes: ARID1A, PTEN, PIK3CA, KRAS, CTNNB1, PPP2R1A, TP53. We found that PTEN mutations are more frequent in low-grade endometrial endometrioid carcinomas (67%) compared with low-grade ovarian endometrioid carcinomas (17%) (P<0.0001). By contrast, CTNNB1 mutations are significantly different in low-grade ovarian endometrioid carcinomas (53%) compared with low-grade endometrial endometrioid carcinomas (28%) (P<0.0057). This difference in CTNNB1 mutation frequency may be reflective of the distinct microenvironments; the epithelial cells lining an endometriotic cyst within the ovary are exposed to a highly oxidative environment that promotes tumorigenesis. Understanding the distinct mutation patterns found in the PI3K and Wnt pathways of ovarian and endometrial endometrioid carcinomas may provide future opportunities for stratifying patients for targeted therapeutics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915240PMC
http://dx.doi.org/10.1038/modpathol.2013.107DOI Listing

Publication Analysis

Top Keywords

endometrioid carcinomas
32
endometrial endometrioid
16
ovarian endometrioid
16
endometrioid
8
carcinomas
8
mutation profiles
8
ovarian
5
ovarian endometrial
4
carcinomas distinct
4
distinct ctnnb1
4

Similar Publications

Endometrial carcinoma is one of the most common gynecologic cancers worldwide. The condition typically occurs after menopause; however, young women under the age of 40 years can also be diagnosed with the disease. Providers may delay diagnosis in young patients due to nonspecific presentation or low clinical suspicion.

View Article and Find Full Text PDF

Background: Endometrial carcinoma (EC) represents a significant clinical challenge due to its pronounced molecular heterogeneity, directly influencing prognosis and therapeutic responses. Accurate classification of molecular subtypes (CNV-high, CNV-low, MSI-H, POLE) and precise tumor mutational burden (TMB) assessment is crucial for guiding personalized therapeutic interventions. Integrating proteomics data with advanced machine learning (ML) techniques offers a promising strategy for achieving precise, clinically actionable classification and biomarker discovery in EC.

View Article and Find Full Text PDF

Background: Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.

View Article and Find Full Text PDF

Objective: This study compared the oncological outcomes of Pure Uterine Serous Carcinomas (p-USC) and p53-Abnormal Grade 3 Endometroid Endometrial Tumours (p53 Abn G3-EEC).

Methods: A retrospective study was conducted at Amrita Institute of Medical Sciences from February 1, 2015, to December 31, 2020, analysing patients diagnosed with P-USC and p53 Abn G3-EEC. The primary objective was to compare the 5-year Progression-Free Survival (PFS) between two groups.

View Article and Find Full Text PDF

Race and neighborhood disadvantage in patients with stage I-III endometrioid endometrial carcinoma treated at a tertiary referral center.

Gynecol Oncol

September 2025

University of Chicago, Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Chicago, IL 60637, USA; University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL 60637, USA.

Objective: To identify associations between race, neighborhood disadvantage, and outcomes in women with stage I-III endometrioid endometrial cancer (EEC) treated at a tertiary referral center.

Methods: This retrospective tumor registry study included patients with stage I-III EEC between 1/2006 and 12/2022. Progression-free (PFS) and overall survival (OS) were analyzed by race and neighborhood disadvantage, stratified by Area Deprivation Index (ADI; national quartile).

View Article and Find Full Text PDF